Logos Global Management LP Viridian Therapeutics, Inc.\De Transaction History

Logos Global Management LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$17.09 - $23.82 $1.71 Million - $2.38 Million	100,000 Added 16.67%	700,000 $12.3 Million
Q4 2023 Feb 14, 2024	SELL	$11.12 - $22.5 $5 Million - $10.1 Million	-450,000 Reduced 42.86%	600,000 $13.1 Million
Q3 2023 Nov 14, 2023	SELL	$15.16 - $24.7 $1.14 Million - $1.85 Million	-75,000 Reduced 6.67%	1,050,000 $16.1 Million
Q2 2023 Aug 14, 2023	BUY	$22.57 - $29.67 $3.95 Million - $5.19 Million	175,000 Added 18.42%	1,125,000 $26.8 Million
Q1 2023 May 15, 2023	SELL	$25.04 - $37.6 $1.25 Million - $1.88 Million	-50,000 Reduced 5.0%	950,000 $24.2 Million
Q3 2022 Nov 14, 2022	BUY	$10.7 - $25.5 $10.7 Million - $25.5 Million	1,000,000 New	1,000,000 $20.5 Million
Q4 2021 Feb 14, 2022	SELL	$15.65 - $21.5 $23.5 Million - $32.3 Million	-1,500,000 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$10.69 - $18.2 $16 Million - $27.3 Million	1,500,000 New	1,500,000 $24.7 Million
Q2 2021 Aug 16, 2021	SELL	$14.34 - $18.67 $7.89 Million - $10.3 Million	-550,000 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$15.5 - $24.93 $8.53 Million - $13.7 Million	550,000 New	550,000 $9.19 Million

179

76.8M

581K

439K

Ticker VRDN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,888,900
Market Cap $839M
Description
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...

Get notified when there are updates to the investment portfolio of Logos Global Management LP, based on Form 13F filings with the SEC.

Stay updated on Logos Global Management LP with notifications on news.